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Lenalidomide has been proven to be effective but with a distinct anddifficult to manage toxicity profile in the context of chronic lym-phocytic leukemia, potentially hampering combination treatment
with this drug. We conducted a phase 1-2 study to evaluate the efficacy
and safety of six cycles of chlorambucil (7 mg/m2 daily), rituximab (375
mg/m2 cycle 1 and 500 mg/m2 cycles 2-6) and individually-dosed
lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line
treatment of patients with chronic lymphocytic leukemia unfit for treat-
ment with fludarabine, cyclophosphamide and rituximab. This was fol-
lowed by 6 months of 10 mg lenalidomide monotherapy (induction-II).
Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed
induction-I and 36 (68%) completed induction-II. In an intention-to-treat
analysis, the overall response rate was 83%. The median progression-
free survival was 49 months, after a median follow-up time of 27
months. The 2- and 3-year progression-free survival rates were 58% and
54%, respectively. The corresponding rates for overall survival were
98% and 95%. No tumor lysis syndrome was observed, while tumor
flair reaction occurred in five patients (9%, 1 grade 3). The most com-
mon hematologic toxicity was grade 3-4 neutropenia, which occurred in
73% of the patients. In conclusion, addition of lenalidomide to a
chemotherapy backbone followed by a fixed duration of lenalidomide
monotherapy resulted in high remission rates and progression-free sur-
vival rates, which seem comparable to those observed with novel drug
combinations including novel CD20 monoclonal antibodies or kinase
inhibitors. Although lenalidomide-specific toxicity remains a concern, an
individualized dose-escalation schedule is feasible and results in an
acceptable toxicity profile. EuraCT number: 2010-022294-34.
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Although important progress has been made in the man-
agement of chronic lymphocytic leukemia (CLL) in the last
decades, treatment for elderly and unfit patients is still not
optimized. Despite clear advantages of the chemotherapeu-
tic drug chlorambucil in elderly patients, with respect to
toxicity, oral administration and low costs, its efficacy as a
single agent is low in CLL. 
The CLL11 trial found that the progression-free survival
of patients given combination treatment with chlorambucil
and rituximab or chlorambucil and obinutuzumab was
longer than that of patients given chlorambucil monothera-
py (median progression-free survival: 15.4 months and 29.2
months, respectively, versus 11.1 months).1 Since the publi-
cation of the findings of this trial, treatment with chloram-
bucil and an anti-CD20 monoclonal antibody has become
the standard, first-line therapy for elderly patients and those
unfit for treatment with fludarabine, cyclophosphamide
and rituximab (FCR).2 Nevertheless, relapses occur in virtu-
ally all patients within 3.5 years.3 A more recent trial com-
pared chlorambucil monotherapy with continuous treat-
ment with the Bruton tyrosine kinase inhibitor ibrutinib
and showed improved progression-free survival and overall
survival in patients treated in the ibrutinib arm.4 Based on
this study, ibrutinib also acquired a label for first-line treat-
ment for previously untreated FCR-unfit patients.
However, treatment with targeted inhibitors is not consid-
ered curative, most likely because of the pronounced evolu-
tionary capacity CLL cells resulting in the emergence of
drug-resistant clones.5 Moreover, prolonged treatment with
targeted inhibitors has significant medical, social, and eco-
nomic costs. It is, therefore, necessary to optimize therapy
for elderly and FCR-unfit patients and combine therapies
with other mechanisms of action.
Lenalidomide is an oral immunomodulatory drug that
has multiple mechanisms of action on the immune system.
It alters the interaction between CLL cells and the protec-
tive microenvironment and stimulates the cytotoxicity of
natural killer cells against CLL cells. Lenalidomide restores
the immunological synapse between T cells and CLL cells,
reversing T-cell dysfunction and enhancing the ability of
immune recognition of tumor cells. In addition, lenalido-
mide directly affects cell proliferation through upregulation
of p21 activity. This effect is independent of the TP53 path-
way and could thus be applicable for patients with TP53
dysfunction too.6-8
The overall response rates to lenalidomide as a single
agent are low with few complete remissions (overall
response rate range: 32%-72%, complete remission rate
range: 0%-10%) in previously untreated or treated CLL
patients.9-13 Addition of rituximab to lenalidomide resulted
in an increased overall response rate of 78% with complete
remissions in 11% of patients with relapsed/refractory
CLL.14-16 Moreover, addition of rituximab seems to diminish
tumor lysis syndrome and tumor flare reaction, which are
distinct and difficult to manage toxicity profiles reported in
CLL patients treated with lenalidomide.16
Given the key role of the microenvironment in chemore-
sistance, addition of lenalidomide to chlorambucil and rit-
uximab may result in further improvement of response
rates.6 Furthermore, extended duration of treatment has
been reported to improve both the overall response rate and
quality of responses.16
Currently it is not known whether combination treat-
ment with lenalidomide, rituximab and chlorambucil is fea-
sible in terms of safety and efficacy. As such, we conducted
a phase 1-2 study in which six cycles of triple therapy fol-
lowed by six cycles of lenalidomide monotherapy were
tested in elderly and FCR-unfit patients with advanced, pre-
viously untreated CLL.  
Methods
Study design and patients 
This prospective, open-label study consisted of a phase 1
dose-finding part and a phase 2 efficacy part. Treatment-naïve
patients diagnosed with immunophenotypically confirmed CLL,
aged 65 – 80 years or 18 – 64 years with a Cumulative Illness
Rating Scale score ≥7, in Binet C (Rai III-IV) stage, or with con-
firmed active disease in Binet A or B (Rai 0-II) stage were
enrolled.17 A complete list of inclusion and exclusion criteria is
presented in Online Supplementary Table S1.   
Treatment 
All patients were treated with six cycles (every 28 days) of a
combination of chlorambucil (p.o. cycles 1-6, days 1 – 7), ritux-
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Figure 1. Schedule of phase 2 of the study. *or maximum tolerated dose
imab (375 mg/m2 i.v. cycle 1, day 1; 500 mg/m2 i.v. cycles 2-6,
day 1) and lenalidomide (induction-I). The dose of lenalidomide
was escalated from 2.5 mg to 10 mg during induction-I.
Subsequently patients were treated with six cycles of lenalido-
mide 10 mg p.o. daily (induction-II) (Figure 1). The criteria for
discontinuation and restarting lenalidomide and prophylactic
treatment are presented in Online Supplementary Tables S2, S3,
and S4, respectively. 
Study phase 1 
This phase of the study focused on determining the maximum
tolerated dose and the recommended dose level of chlorambucil
in combination with rituximab and lenalidomide. Six patients
started combination treatment with chlorambucil at dose level 1
(7 mg). If no more than one dose-limiting toxicity occurred
(Online Supplementary Table S5), the dose was escalated to 10 mg
(dose level 2) for the subsequent patients, on the basis of which
the recommended dose level was established. 
Study phase 2 
The aim of this phase was to evaluate the efficacy of chloram-
bucil, at the recommended dose level, in combination with rit-
uximab and lenalidomide, in terms of overall response rate. 
Endpoints 
The protocol endpoints are presented in Online Supplementary
Table S6. Responses were determined according to the 2008
International Workshop on CLL criteria17 and evaluated after
cycle 3 (clinically), after cycle 6, at the end of the study treat-
ment and during follow-up. The presence of minimal residual
disease, as measured in the peripheral blood, was determined
centrally using six-color flow cytometry.18 Toxicity was reported
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0.
The Cairo-Bishop grading classification19 and CTCAE version
3.020 were used to grade tumor lysis syndrome and tumor flare
reaction, respectively.20
Statistical analysis 
All analyses were performed according to the intention-to-
treat principle but, in agreement with the protocol, excluding
patients not considered eligible in hindsight. The patients’ char-
acteristics and treatment toxicity were summarized by descrip-
tive cross-tabulations. Responses were tabulated according to
the fraction of the optimal dose of lenalidomide in each cycle
(<90% versus ≥90%). The Kaplan-Meier method was used for
time-to-event analysis. All statistical analyses were performed
using STATA Statistical Software version 14. 
Ethics 
Written informed consent was obtained before enrollment in
the trial. The study was approved by an accredited Ethical
Committee and Institutional Review Board and was performed
according to the Declaration of Helsinki, the International
Conference on Harmonization Good Clinical Practice
Guidelines and the European Union Clinical Trial Directive
(2001/20/EG). The study was registered with EuraCT number
2010-022294-34.
Results
Between September 20, 2011 and October 18, 2015, 63
previously untreated patients with CLL from 26 centers
in the Netherlands were enrolled in this study.  
Maximum tolerated dose and recommended dose level
of chlorambucil given in combination with rituximab
and lenalidomide
Twelve patients were included in phase 1 of this study
aimed at determining the recommended dose level of
chlorambucil in combination with rituximab and
lenalidomide. In the first dose level group 7 mg/m2 chlo-
rambucil), no dose-limiting toxicity was observed.
Subsequently, six patients were included in the second
dose level, of 10 mg/m2, of chlorambucil. Again, no dose-
limiting toxicities were observed at this dose level. There
were no differences in the proportions of adverse or
severe adverse events between the groups treated with
the two different doses. Lenalidomide dose modifications
were more frequently applied in the second dose level
group. Despite the lack of significant differences in toxic-
ity between the two groups treated with different chlo-
rambucil dosages, the principal investigators, with sup-
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Figure 2. Flowchart of number of
patients through the study protocol
and off protocol, with reasons. Chlor
7: chlorambucil 7 mg/m2; Chlor 10:
chlorambucil 10 mg/m2; SLL: small
lymphocytic leukemia. 
port of the data safety and monitoring board, decided to
continue part 2 of the trial with the recommended dose
level of 7 mg/m2, day 1-7, of chlorambucil (dose level 1)
based on toxicity reports of an international phase 3
study.9
Phase 2 patients and study treatment
For the phase 2 part of the trial, 57 patients were includ-
ed of whom four were subsequently excluded because
they were not eligible in hindsight having  been found to
have small lymphocytic lymphoma. Combination treat-
ment with chlorambucil, rituximab and lenalidomide was
started in 53 patients (induction-I). The patients’ disposi-
tion through the trial is summarized in Figure 2 and the
clinical, biological and cytogenetic characteristics of the
patients are reported in Table 1. The median age of the
patients was 71 years (range, 60 – 80).  Mutational status
could be assessed in 39 patients. The IGVH genes were
mutated in 20 patients (51%) and unmutated in 19
patients (49%). Deletion of chromosome 17p was found
in eight of 51 (17%) patients. Eight of 50 (15%) and 23 of
50 (43%) patients had deletion of chromosome 11q and
13q, respectively. 
Forty-seven (89%) patients completed the six planned
courses of chlorambucil, rituximab and lenalidomide.
Treatment was prematurely discontinued in 11 patients
(21%). Reasons for discontinuation were excessive toxic-
ity (n=8: 4 cases of skin toxicity, 1 grade 3 allergic reac-
tion, 1 case of neuropathy, 1 acute coronary syndrome
and 1 case of mucositis), refusal (n=2) and progression
(n=1). 
Following combination treatment, lenalidomide
monotherapy was initiated in 42 patients (79%) (induc-
tion-II). Treatment was prematurely discontinued during
induction-II in six patients, due to excessive toxicity (n=5:
3 cases of hematologic toxicity in the form of persistent
neutropenia and 2 cases of diarrhea with no improve-
ment following dose reductions.) or refusal (n=1).
Treatment was completed according to the protocol in 36
(68%) patients. 
The full dose of lenalidomide during induction-I was
given to 76% of the patients in cycle 1, to 57% of the
patients in cycle 2, to 50% in cycle 3, 57% in cycle 4, 53%
in cycle 5 and 51% in cycle 6 (Figure 3). During cycle 6 of
induction-II, 25 (69%) patients received lenalidomide at
the full dose. The median dose of lenalidomide according
to the prescribed protocol dosing was 86.7% (range,
10%-101%) and 99.7% (range, 25%-104%) in induction-
I and induction-II, respectively. 
Response evaluation 
On an intention-to-treat basis, response was analyzed
in 53 patients at the end of induction-I. The overall
response rate was 83% (95% confidence interval: 72%-
92%), which resulted in a positive trial based on the
phase 2 design as stated in the protocol. The responding
patients all achieved a partial response and no complete
responses were observed on induction-I (Figure 4).  
Responses at the end of induction-II were evaluated in
all patients (n=42) who started this phase of induction.
The overall response rate was 93% (95% confidence
interval: 79%-98%) and consisted of 14% complete
responses (n=6) and 79% partial responses (n=33). The
disease remained stable in two (5%) patients and pro-
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Figure 3. Lenalidomide dosing: cumulative dose of lenalidomide compared to
optimal dose per treatment cycle during induction-I. Lena: Lenalidomide.
Table 1. Patients’ characteristics.
Patients’ characteristics                              Number of patients (n=53) 
Median age [range], years                                                   71 [60-80]
Age, n. (%)
<65 years                                                                                     1 (2)
≥65 to ≤70 years                                                                      25 (47)
>70 years                                                                                  27 (51) 
Male sex, n. (%)                                                                        29 (55)
RAI stage, n. (%)
0-I                                                                                                11 (21)
II                                                                                                  10 (19)
III                                                                                                 22 (42)
IV                                                                                                 10 (19)
CIRS score − n. (%)
≤6                                                                                                47 (87)
>6                                                                                                  4 (8)
Unknown                                                                                      2 (4)
Median CIRS [range]                                                                1 [0-9]
Lactate dehydrogenase, n. (%) 
Lactate dehydrogenase ≤ upper level of normal            33 (62)
Lactate dehydrogenase > upper level of normal            18 (34)
Unknown                                                                                      2 (4)
Median β2-microglobulin [range] (n=43)                    3.8 [1.6-10.4]
IGVHmutational status − n. (%) 
Mutated                                                                                     20 (38)
Unmutated                                                                                19 (36)
Unknown                                                                                   14 (26)
Cytogenetic abnormalities − n. (%) 
Del17p                                                                               8 out of 51 (17%)
Del11q                                                                               8 out of 51 (17%)
Trisomy 12                                                                       12 out of 50 (24%)
Del 13q                                                                             23 out of 50 (46%)
CRS: Cumulative Illness Rating Scale; IGVH: immunoglobulin variable region heavy
chain; del: deletion.
gressed in one (2%) patient. Improvement of the response
after induction-II was observed in eight (15%) of all
patients who started induction-I: six patients (11%) had
an improvement from a partial to complete response and
two patients (4%) had an improvement from stable dis-
ease to a partial response in induction-II. 
Flow-based minimal residual disease analysis was per-
formed on peripheral blood in 41 patients. Of these
patients, four (8%) achieved minimal residual disease
negativity after induction-I and an additional two (4%)
after induction-II.
Survival 
After a median follow-up of 27 months, the median pro-
gression-free survival was 49 months (Figure 5A). At 2 and
3 years, 58% [standard error (SE)=8%] and 54% (SE=8%)
of the patients, respectively, were alive without progres-
sion. The 3-year progression-free survival rate of patients
with a deletion of chromosome 17p [del(17p); n=8] was
lower than that of patients without this deletion (38% ver-
sus 59%, respectively). For patients who started induction-
II (n=42), the subsequent progression-free survival was 41
months and the 2-year progression-free survival rate was
56% (SE=9%). The median event-free survival was 49
months and the event-free survival rate at 3 years was 53%
(SE=8%) with 13% (SE=5%) non-responders and 34%
(SE=8%) with progressive disease. Of the patients with
progressive disease, one patient started the next treatment
before progressing. During follow-up the median overall
survival was not reached with 2- and 3-year overall sur-
vival rates of 98% (SE=2%) and 95% (SE=3%), respective-
ly (Figure 5B). With regard to overall survival following
induction-II, no deaths had occurred among the patients
who started induction-II.
Safety 
Two patients included in the phase 2 part of the trial
developed a grade 4 adverse event, consisting of neu-
tropenic sepsis. These severe adverse events occurred
during induction-I in cycle 2 and cycle 5. No grade 4
adverse events were observed during induction-II. Tumor
lysis syndrome did not occur. A tumor flare reaction was
reported in five patients (9%) and was ≤ grade 2 in four
patients and grade 3 in one patient. Six patients devel-
oped a secondary malignancy, which was localized skin
cancer in all but one. One patient had a solid tumor. 
Grade 3-4 neutropenia occurred in 39 (73%) and 27
(64%) patients during induction-I and induction-II,
respectively, which prompted granulocyte colony-stimu-
lating factor administration as shown per cycle in Online
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Table 2. Grade 3-4 toxicities.
                                                                                                                      Number of patients (%)
                                                                                    Induction I                  Induction II
                                                                                                             Grade 3                           Grade 4                        Grade 3                Grade 4
Hematologic toxicity                                                                                                                                                                         
Neutropenia                                                                                                           14 (26%)                                25 (47%)                           14 (33%)                 13 (31%)
Thrombocytopenia                                                                                                  5 (9%)                                    3 (6%)                              5 (12%)                     2 (5%) 
Anemia                                                                                                                       1 (2%)                                         -                                           -                                 -
Other adverse events                                                                                                                                                                       
Any                                                                                                                            21 (40%)                                  2 (4%)                              8 (19%)                           -
Infections and infestations                                                                                   5 (9%)                                         -                                   4 (10%)                           - 
General disorders and administration site conditions                                6 (11%)                                        -                                           -                                 -
Skin and subcutaneous tissue disorders                                                         6 (11%)                                        -                                    3 (7%)                            - 
Respiratory, thoracic and mediastinal disorders                                            3 (6%)                                         -                                           -                                 -
Musculoskeletal and connective tissue disorders                                         1 (2%)                                         -                                           -                                 -
Nervous system disorders                                                                                   1 (2%)                                         -                                           -                                 -
Blood and lymphatic disorders                                                                            1 (2%)                                         -                                           -                                 -
Cardiac disorders                                                                                                   1 (2%)                                   1 (2%)                               1 (2%)                           - 
Immune system disorders                                                                                   2 (4%)                                         -                                           -                                 -
Metabolism and nutrition disorders                                                                  2 (4%)                                         -                                           -                                 -
Renal and urinary disorders                                                                                1 (2%)                                         -                                           -                                 -
Investigations                                                                                                          1 (2%)                                   1 (2%)                                    -                                 -
Psychiatric disorders                                                                                             1 (2%)                                         -                                           -                                 -
Figure 4. Responses after induction-I and -II. PD: progressive disease; SD: sta-
ble disease; PR: partial response; CR: complete response. 
Supplementary Table S7. Neutropenic sepsis occurred in
two (4%) patients. Grade 3-4 thrombocytopenia was
recorded in 15% and 17% of the patients after induction-
I and induction-II, respectively. Despite this, no grade 3-4
bleeds occurred. Grade 3-4 anemia was recorded in 2% of
the patients during induction-I. Although all patients
received thromboembolic prophylaxis, two patients (4%)
had a thromboembolic event (i.e. deep vein thrombosis
and thrombophlebitis despite prophylactic aspirin). 
Grade 3-4 skin and subcutaneous tissue disorders
occurred in six patients (11%). Thirteen patients (25%)
developed grade 2 skin toxicity. Other grade 3-4 toxicities
occurred in 26 patients (49%), of which 23 (44%) during
induction-I and eight (19%) during induction-II. The
majority of these toxic events were infections (15%), gas-
trointestinal disorders (15%), or general disorders and
administration site conditions (11%) (Table 2). 
Two patients (4%) have died during disease progres-
sion. These deaths occurred  19 and 24 months after reg-
istration in the study. 
Discussion 
In this prospective, open label, phase 1/2 study, we
investigated the activity of lenalidomide in combination
with chlorambucil and rituximab for elderly and FCR-
unfit patients with previously untreated CLL. 
After a median follow-up of 27 months, the median
progression-free survival in our study was 49 months.
The 2- and 3-year progression-free survival rates were
58% and 54%, respectively. The corresponding overall
survival rates were 98% and 95%. Since this study is the
first to investigate triple treatment with chlorambucil, rit-
uximab and lenalidomide, direct comparison with other
clinical trials is limited.
Recently, novel first-line regimens have been tested in
frail, elderly patients: e.g., chlorambucil as a backbone with
novel CD20 monoclonal antibodies and novel chemother-
apy-free combinations. The CLL11 trial compared treat-
ment with chlorambucil monotherapy, chlorambucil and
rituximab or chlorambucil and obinutuzumab.1 The medi-
an progression-free survival was 16.3 months for patients
treated with chlorambucil and rituximab and 26.7 months
for those treated with chlorambucil and obinutuzumab.
The COMPLEMENT-1 trial investigated treatment with
chlorambucil and ofatumumab, comparing this with chlo-
rambucil monotherapy.21 After a median follow-up of 29
months, the median progression-free survival was 22
months and the overall response rate was 82% for patients
treated with chlorambucil and ofatumumab. 
With regards to chemotherapy-free combinations of
lenalidomide with rituximab, an overall response rate of
88% and a median progression-free survival of 20 months
were observed in a phase 2 study.14 In the phase 1b/2
PCYC-1102/1103 studies, treatment with ibrutinib result-
ed in overall response rates of 87% and 89% in treat-
ment-naïve and relapsed/refractory patients, respectively.
The overall response rates were 97%, 89% and 79% in
relapsed/refractor patients with a del(11q), complex kary-
otype and del(17p), respectively. After a median follow-
up of 61.5 months, the median progression-free survival
had not been reached in treatment-naïve patients and was
51 months in relapsed/refractory patients.22,23
With all the caveats necessary when comparing differ-
ent trials, the progression-free survival and overall
response rates in the current study seem at least compa-
rable to those observed with chlorambucil in combina-
tion with novel CD20 monoclonal antibodies and those
observed with kinase inhibitors. 
The dose of chlorambucil used in our study was 7 mg/m2
on days 1-7 of cycles 1-6. Chlorambucil was administered
in combination with rituximab and lenalidomide during
six cycles. In the COMPLEMENT-1 trial patients were
treated with 10 mg/m2 of chlorambucil on days 1-7 during
a minimum of three and a maximum of 12 cycles. In the
CLL11 trial, chlorambucil was administered at a dose of 0.5
mg/kg on days 1 and 15 of cycles 1-6. 
Lenalidomide was started at a dose of 2.5 mg/day, and
was steadily increased to 10 mg/day which was main-
tained until cycle 6, provided there were no dose-limiting
toxicities. The escalation scheme of lenalidomide was
previously described in combination with rituximab in a
phase 2 trial.14 However, in that study lenalidomide was
administered for 21 days, followed by a period of rest
each cycle. The use of a continuous dose of lenalidomide
A.P. Kater et al.
152 haematologica | 2019; 104(1)
Figure 5.  Survival outcomes after registration. (A) Progression-free survival and (B) overall survival, with the numbers of patients at risk at 1, 2 and 3 years.
A B
in combination with rituximab was previously described
and was proven to be safe and effective.15,24
Following induction-I, patients received an additional
six cycles of monotherapy with lenalidomide 10 mg/day.
As previously reported, responses can improve with
lenalidomide consolidation treatment.11,25-27 In addition,
the CLLM1 study showed that lenalidomide (5-10-15
mg/day) can be efficaciously used as maintenance treat-
ment, prolonging the time to progression as compared
with placebo, in first-line patients with CLL who do not
achieve minimal residual disease negativity following
chemoimmunotherapy induction.25
Although lenalidomide-specific toxicity remains a con-
cern, an individualized dose-escalation schedule is feasi-
ble and results in an acceptable toxicity profile and less
frequent occurrence of tumor lysis syndrome and tumor
flare reactions. Grade 3-4 toxicities were reported in 26
(49%) patients. The most frequently reported toxicities
were infections and gastrointestinal disorders. Despite
prophylaxis with granulocyte colony-stimulating factor,
64% and 73% of patients developed grade 3-4 neutrope-
nia. Similar percentages were observed in the GIMEMA
trial, in which patients were treated with a combination
of fludarabine, lenalidomide and rituximab.9 The rate of
grade 3-4 toxicities reported with ofatumumab and chlo-
rambucil in the COMPLEMENT-1 trial was 50%,21 which
is comparable to the rate in our study. Treatment with
ibrutinib, as described in the PCYC-1102/1103 studies,4
was less toxic than treatment with chlorambucil, ritux-
imab and lenalidomide.
The ORIGIN study, in which lenalidomide monothera-
py was compared with chlorambucil, was stopped pre-
maturely after an imbalance in deaths and treatment-
emergent adverse events in the lenalidomide arm.10 Based
on these observations, lenalidomide monotherapy was
not recommended as first-line treatment in CLL patients,
particularly in those who are elderly and/or frail.
Although our study has shown that adverse events and
deaths can be reduced by using individualized dose
schedules, intensive monitoring is required. The high
death rate observed in the ORIGIN study in lenalido-
mide-treated patients10 was not replicated in our study. 
Due to rapid developments, the clinical impact of our
study might be limited. Although chemo-immunothera-
py is still considered a standard first-line option in CLL
patients without del17p/TP53 mutation, phase 2 as well
as phase 3 studies examining new chemotherapy-free
regimens show a high proportion of minimal residual dis-
ease-negative responses.28 Nevertheless, data currently
available imply that patients will relapse even following
treatment with novel agents. Based on the findings of this
study and on lenalidomide’s unique mechanisms of
action,6 there might be a role for this drug or for the
newer immunomodulatory treatments either in combina-
tion with novel agents, or in patients who are not eligible
for novel therapies such as ibrutinib. 
In conclusion, our study showed that triple treatment
with chlorambucil, rituximab and lenalidomide is an effec-
tive therapy in previously untreated elderly and FCR-unfit
patients with CLL. Intensive monitoring is of paramount
importance to minimize toxicity and ensure safety. 
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